These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 9725050)

  • 21. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
    Toppmeyer D; Seidman AD; Pollak M; Russell C; Tkaczuk K; Verma S; Overmoyer B; Garg V; Ette E; Harding MW; Demetri GD
    Clin Cancer Res; 2002 Mar; 8(3):670-8. PubMed ID: 11895894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Late phase II study of CGS16949A, a new aromatase inhibitor--a multicentral cooperative study (Western Japan Group)].
    Wada T; Nomura Y; Oohashi Y; Abe O; Koyama H; Takashima S
    Gan To Kagaku Ryoho; 1994 Mar; 21(4):485-93. PubMed ID: 8129389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer].
    Wada N; Kobayashi H; Oka S; Ando J; Tamura H
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1935-42. PubMed ID: 12465393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of cholesterol-rich nanoparticles that bind to lipoprotein receptors as a vehicle to paclitaxel in the treatment of breast cancer: pharmacokinetics, tumor uptake and a pilot clinical study.
    Pires LA; Hegg R; Valduga CJ; Graziani SR; Rodrigues DG; Maranhão RC
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):281-7. PubMed ID: 18365196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G;
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):951s-8s. PubMed ID: 15701892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A phase I study of combination chemotherapy using TS-1 and pirarubicin (THP) for advanced gastric cancer].
    Yamamura Y; Kodera Y; Tanemura H; Oshita H; Miyashita K; Fujimura T;
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):361-5. PubMed ID: 15045941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
    Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Weekly administration of low-dose paclitaxel for advanced or metastatic breast cancer].
    Uno Y; Hirano M; Murakami N; Kikuchi T; Nozawa H; Okuda T; Oya J; Kikkawa H
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):227-32. PubMed ID: 11865628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
    Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
    J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic results in recurrent breast cancer with the use of Bestrabucil (KM2210)].
    Ueda T; Sakai K; Morimoto K; Nakatani S
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3285-9. PubMed ID: 3688892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.
    de Vos D; Slee PH; Briggs RJ; Stevenson D
    Cancer Chemother Pharmacol; 1998; 42(6):512-4. PubMed ID: 9788580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical effect of Peplomycin on recurrent breast cancer].
    Kimura M; Koida T; Fukuda T
    Gan To Kagaku Ryoho; 1983 Jul; 10(7):1665-9. PubMed ID: 6191688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anticancer effect of peplomycin on advanced recurrent breast cancer].
    Nakanishi Y; Hata Y; Sato N; Kawamura A; Uemura T; Hasegawa M; Miyakawa K; Nakamura T; Kawai M; Kawamoto K
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1428-33. PubMed ID: 6204596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
    Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
    J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.
    Kohler PC; Hamm JT; Wiebe VJ; DeGregorio MW; Shemano I; Tormey DC
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S19-26. PubMed ID: 2149280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of chemo-endocrine therapy in recurrent breast cancer].
    Kawaura Y; Hashizume Y; Ishida K; Katada S; Hirano M; Yamada T; Iwa T
    Nihon Gan Chiryo Gakkai Shi; 1986 Feb; 21(1):68-72. PubMed ID: 3701167
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.